TIDES USA 2026
5.11 – 5.14 | Boston, MA, USA
5.11 – 5.14 | Boston, MA, USA
5.11 – 5.15 | Boston, MA, USA
4.14 – 4.16 | Copenhagen, Denmark
3.18 – 3.19 | Boston, MA, USA
3.17 – 3.19 | Austria Center, Vienna, Austria
3.06 – 3.07 | University of Michigan, MI, USA
1.12 – 1.14 | San Francisco, CA, USA
11.11 – 11.13 | Berlin, Germany
11.11 – 11.13 | Congress Center Basel, Basel, Switzerland
10.19 – 10.22 | Budapest, Hungary
10.18 | Budapest, Hungary
9.21 – 9.25 | Hôtel Chéribourg, Magog, Quebec, Canada
9.16 – 9.18 | Coronado, CA, USA
Introduction Singapore, 5 May 2026: Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end...
Introduction In Singapore, January 12, 2026; Hongene Biotech announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use in mRNA...
Introduction SINGAPORE (July 10th, 2025) – Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, today announced its critical role in advancing DNV001, a...
Hongene launches operations at its new mRNA CDMO GMP facility, ensuring efficient, high-quality production of mRNA therapeutics and vaccines. The new facility consists of more than 30,000 sq. ft. of...
SAN DIEGO, Calif., April 24, 2024 (BUSINESS WIRE), Hongene Biotech Corporation, a global specialist in nucleic acid raw material supply and CDMO services, and n-Lorem, a nonprofit foundation formed a new partnership to support...
NEWS Recently, at Hongene Biotech's high-tech GMP facility, Hongene Biotech and Syensqo officially signed a strategic cooperation framework agreement. This milestone event signifies that both parties will engage in deeper...
NEWS On September 9, 2024, ReciBioPharm, a US-based contract development and manufacturing organization (CDMO) service provider, and Hongene Biotech, a leading supplier in the nucleic acid raw materials field, announced...
In recent years, dual-targeting oligonucleotide drugs have become one of the hottest fields in the global pharmaceutical industry due to their advantages of synergistic effects and avoiding combination therapy. Despite...
Hypercholesterolemia is one of the most common chronic metabolic disorders. Its core characteristic is abnormally elevated levels of "bad cholesterol," or low-density lipoprotein cholesterol (LDL-C), which can form atherosclerotic plaques...
Introduction The widespread application of CRISPR-Cas technology in the gene editing field is driving rapid growth in the demand for sgRNA synthesis. However, the traditional SPOS (Solid-Phase Oligonucleotide Synthesis) method...
Introduction siRNA, as a type of RNA interference (RNAi) technology, has demonstrated significant value and potential in the fields of gene silencing and targeted therapy. During the development of siRNA...
Introduction December 9, 2024 – A research team led by Professor Phil S. Baran from Scripps Research in the United States, in collaboration with researchers from Elsie Biotechnologies and Hongene...
Introduction Nucleic acid drugs, including small nucleic acids and mRNA drugs, represent a rapidly growing segment within the biopharmaceutical field. With continuous technological iterations, particularly innovations in nucleic acid chemical...
As the market demand for RNA therapeutics such as siRNA and sgRNA is anticipated to grow substantially over the next decade, there is a need for scalable, cost-effective, and sustainable...
As several siRNA assets indicated for treating diseases associated with cardiovascular targets advance toward potential approval, the market demand for high-quality oligonucleotides is anticipated to grow substantially over the next...